Shanghai Allist Pharmaceuticals stock
688578.SSSHHShanghai Allist Pharmaceuticals Co., Ltd., HealthcareISIN CNE100005XJ7
66Score 66 out of 100, Neutral
Price and trend
40 / 100
Price history
−18% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 16% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 38).
The price is 38% below its 52-week high. Largest decline in 6 years: 60% (December 2020 to April 2022).
Chart figures for advanced users
- SMA 50$14.16
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)38
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.57
- The lowest closing price of the last twelve months.
- Resistance$19.95
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Shanghai Allist Pharmaceuticals Co., Ltd. belongs to the Biotechnology industry (China) and, with a market value of $5.61B, is number 69 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $777.91M (up 45.8% year on year) and earnings of $327.12M (up 52.6%).
- MEQIRI Score 66 out of 100 (Neutral): rank 190 of 702 in Healthcare, median 53.
Show more
- The P/E is 12.9 (Biotechnology median 45.8, own median of recent years 25.3).
- Our model puts fair value at $44.35, with the price 72% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 521.2% a year since 2020, Biotechnology median 19.7%.Growth 70
- High return on capitalReturn on invested capital 81.1% in fiscal 2025, Biotechnology median 4.9%.Profitability 92
- Modestly valuedP/E 12.9, Biotechnology median 45.8, own median 25.3.Valuation 88
Weaknesses
- Margin may fall backOperating margin 49.8%, average of the prior years 16.2%, which ranged from −55,350.1% to 45.9%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.
- DilutionShare count up 22% since 2020.
- Volatile share priceVolatility 51% a year over the last 12 months.
Its standout strengths are profitability and valuation, while technical analysis and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 67 to 66.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $31.68 and expensive above $73.92 (uncertainty high, based on the price swings of the past year).
Valuation metrics
From earnings times the industry P/E (45.8) alone; there are no viable cash flows for the cash-flow model.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 38.5% on the twelve months before. Revenue has grown strongly since 2017, at around 126% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 97%, operating 50%, net 42%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 28 Apr 2027in 166 days
- Last reported
- 27 Oct 2026EPS reported $0.26
Analyst estimates
Earnings estimates have barely changed since 28 Oct 2026.
- Earnings per share
- $0.95−2.3%
- Revenue
- $1.03B−0.5%
- Earnings per share
- $1.11+0.7%
- Revenue
- $1.2B+0.2%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Shanghai Allist Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Hangzhou Tigermed Consulting300347.SZ $6.12B46
- Mirum PharmaceuticalsMIRM $6.09B38
- Scholar Rock HoldingSRRK $5.71B35
- Anthem BiosciencesANTHEM.NS $5.62B78
- ErascaERAS $5.52B44
- PTC TherapeuticsPTCT $5.29B46
- Dianthus TherapeuticsDNTH $5.21B46
- SK Biopharmaceuticals326030.KS $5.14B67
ETFs that hold Shanghai Allist Pharmaceuticals
Held by 31 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI China A UCITS ETF AccCNAA | 0.09% | 0.35% | €84.92M |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.07% | 0.65% | €10.81M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.02% | 0.60% | €31.52M |
Show 5 more
| Franklin EM Multi-Factor Equity UCITS ETFFLXE | 0.02% | 0.30% | €102.64M |
| HSBC MSCI China UCITS ETFH4ZP | 0.02% | 0.28% | €865.89M |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.02% | 0.30% | €132.6M |
| Franklin FTSE China UCITS ETFFLXC | 0.01% | 0.19% | €1.43B |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.01% | 0.17% | €5.24B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.